KRAS and neoplasm: To this purpose, Hao et al. demonstrated a high concordance of KRAS/BRAF mutational status between primary tumor and serum Exos in patients with CRC, thus representing a possible replacement of tumor biopsy when rapid and non-invasive genotyping is required (73).